Silence Therapeutics PLC (SLN) Peer Comparison

$13.36

$-0.10 (-0.71%)

As on 28-Aug-2026 13:36EDT

Market cap

$825 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

21.3

Div. Yield

0 %

Edit

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Market cap ($ Mln)	825	2,920	2,195	914	839
Revenue ($ Mln)	1	450	549	--	366
Net Profit ($ Mln)	-59.93	-188.21	17.88	-175.85	9.27
Net Margin (%)	-9,755.61	-41.86	3.26	--	2.53
RoE (%)	-118.93	-28.46	1.43	-106.84	3.39
Price to Earnings	--	--	126.30	--	84.64
Price-To-Book	21.30	4.82	1.73	5.59	3.06

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Operating Revenue	0.61	449.61	549.12	0.00	366.45
Cost of Revenue	0.30	195.71	548.01	12.78	49.36
Gross Profit	0.34	269.08	212.72	-17.67	330.63
Operating Expenses	68.01	517.90	35.89	176.86	304.74
Operating Profit (EBIT)	-67.59	-264.00	-34.78	-181.14	12.35
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-59.93	-190.72	20.08	-178.93	15.84
Provision for Tax	0.00	-2.51	1.66	-3.09	6.57
Profit after Tax (Net Income)	-59.93	-188.21	17.88	-175.85	9.27
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Shareholder's Funds	38.47	607.04	1,260.78	160.40	270.49
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	-0.01	39.17	186.25	8.50	104.25
Current Liabilities	12.71	428.58	275.21	54.30	93.25
Total Liabilities	131.44	1,172.38	1,753.10	233.72	499.81

Assets ($ Mln)

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Non-Current Assets	12.13	160.76	183.02	21.30	187.30
Current Assets	94.28	914.04	1,553.41	201.90	280.69
Total Assets	131.44	1,172.38	1,753.10	233.72	499.81
Total Debt*	-0.11	254.58	94.51	21.00	113.30
Net Current Assets	0.00	485.45	0.00	147.60	187.44

Cashflow ($ Mln)

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Cash From Operating Activities	-62.27	-150.79	-64.66	-121.18	54.71
Cash Flow from Investing Activities	-47.99	307.87	-29.41	-1.37	26.25
Cash from Financing Activities	0.02	72.35	7.84	276.18	1.50
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
ROCE (%)	-104.46	-18.15	41.92	-130.25	0.77
ROE (%)	-118.93	-28.46	1.43	-106.84	3.39
ROA (%)	-31.48	-12.55	0.66	-74.77	1.69
EBIT Margin (%)	-9,892.63	-41.09	-6.33	--	8.34
Net Margin (%)	-9,755.61	-41.86	3.26	--	2.53
Cash Profit Margin (%)	-0.03	0.00	--	--	0.00

Growth Ratios

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Revenue Growth (%)	-97.63	5.10	-8.81	-1.00	-99.61
EBIT Growth (%)	26.29	11.36	-76.55	-45.21	523.06
Net Profit Growth (%)	31.32	11.44	-96.17	-43.04	-99.68
EPS Growth (%)	61.06	-1.87	-96.17	7.30	-96.78
Book Value Growth (%)	-86.38	-25.05	2.54	108.85	7.71

Valuation Ratios

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Price / Earnings	-3.24	-11.11	5.08	-9.99	469.58
Price / Book Value	4.61	2.73	1.88	8.70	4.83
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-2.30	-9.39	-25.58	-9.30	36.65
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Debt to Equity	0.00	0.00	0.00	0.00	0.34
Short term debt to equity ratio	0.00	0.40	0.02	0.09	0.03
Current Ratio	7.42	2.13	5.64	3.72	3.01
Quick Ratio	7.42	1.92	5.50	3.72	2.31
Interest Coverage	--	-30.87	-19.05	--	2.08

Operating Efficiency Ratios

	Silence Therapeutics PLC (SLN)	Zai Lab - ADR	HUTCHMED (China) - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Debtors to sales (%)	1,512.64	16.23	21.41	--	15.55
Asset Turnover	0.00	0.30	0.20	0.00	0.67
Receivable days	15,066.04	77.60	104.79	--	51.78
Inventory Days	--	109.55	49.57	--	492.02
Payable days	6,254.47	231.78	47.68	650.68	466.91
Cash Conversion Cycle	--	-44.63	106.67	--	76.89

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly